Pulmonx Debt to Equity Ratio 2019-2025 | LUNG
Current and historical debt to equity ratio values for Pulmonx (LUNG) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pulmonx debt/equity for the three months ending September 30, 2025 was 0.62.
| Pulmonx Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-09-30 | $0.08B | $0.06B | 1.30 |
| 2025-06-30 | $0.08B | $0.07B | 1.13 |
| 2025-03-31 | $0.07B | $0.08B | 0.94 |
| 2024-12-31 | $0.08B | $0.09B | 0.90 |
| 2024-09-30 | $0.07B | $0.09B | 0.78 |
| 2024-06-30 | $0.07B | $0.10B | 0.71 |
| 2024-03-31 | $0.05B | $0.11B | 0.49 |
| 2023-12-31 | $0.06B | $0.12B | 0.50 |
| 2023-09-30 | $0.06B | $0.13B | 0.47 |
| 2023-06-30 | $0.06B | $0.13B | 0.44 |
| 2023-03-31 | $0.06B | $0.14B | 0.40 |
| 2022-12-31 | $0.04B | $0.15B | 0.26 |
| 2022-09-30 | $0.04B | $0.16B | 0.24 |
| 2022-06-30 | $0.04B | $0.17B | 0.24 |
| 2022-03-31 | $0.04B | $0.18B | 0.22 |
| 2021-12-31 | $0.04B | $0.19B | 0.22 |
| 2021-09-30 | $0.04B | $0.20B | 0.22 |
| 2021-06-30 | $0.04B | $0.21B | 0.19 |
| 2021-03-31 | $0.04B | $0.22B | 0.18 |
| 2020-12-31 | $0.04B | $0.23B | 0.17 |
| 2020-09-30 | $0.28B | $-0.21B | -1.34 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | 0.00 | |
| 2019-09-30 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.04B | $-0.03B | -1.56 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.104B | $0.084B |
| Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation is based in Redwood City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $36.700B | 42.44 |
| Tempus AI (TEM) | United States | $12.562B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $8.471B | 68.91 |
| Doximity (DOCS) | United States | $8.256B | 33.99 |
| IRhythm Technologies (IRTC) | United States | $5.440B | 0.00 |
| Hinge Health (HNGE) | United States | $3.912B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.797B | 62.83 |
| Privia Health (PRVA) | United States | $3.064B | 191.62 |
| Heartflow (HTFL) | United States | $2.255B | 0.00 |
| Omnicell (OMCL) | United States | $1.968B | 40.24 |
| 10x Genomics (TXG) | United States | $1.957B | 0.00 |
| Azenta (AZTA) | United States | $1.623B | 66.60 |
| Enovis (ENOV) | United States | $1.514B | 7.95 |
| Clover Health Investments (CLOV) | United States | $1.395B | 0.00 |
| Schrodinger (SDGR) | United States | $1.330B | 0.00 |
| Phreesia (PHR) | United States | $0.980B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.839B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.760B | 0.00 |
| Claritev (CTEV) | United States | $0.619B | 0.00 |
| CapsoVision (CV) | United States | $0.602B | 0.00 |
| Talkspace (TALK) | United States | $0.581B | 117.00 |
| Standard BioTools (LAB) | United States | $0.558B | 0.00 |
| Veradigm (MDRX) | United States | $0.539B | 0.00 |
| Evolent Health (EVH) | United States | $0.460B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.413B | 0.00 |
| Carlsmed (CARL) | United States | $0.344B | 0.00 |
| TruBridge (TBRG) | United States | $0.338B | 15.55 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.321B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.280B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.268B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.174B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.161B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.157B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.149B | 0.00 |
| CareCloud (CCLD) | United States | $0.139B | 7.65 |
| EUDA Health Holdings (EUDA) | Singapore | $0.087B | 0.00 |
| HeartBeam (BEAT) | United States | $0.079B | 0.00 |
| Outset Medical (OM) | United States | $0.076B | 0.00 |
| American Well (AMWL) | United States | $0.075B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.068B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.066B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.044B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.037B | 0.00 |
| 111 (YI) | China | $0.031B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.025B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| Zhongchao (ZCMD) | China | $0.015B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.014B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| PROFUSA (PFSA) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |